Chimerix (CMRX) Reports Preclinical Data Supporting Ongoing Phase 1 Study of New Antiviral for Treatment … – StreetInsider.com


StreetInsider.com
Chimerix (CMRX) Reports Preclinical Data Supporting Ongoing Phase 1 Study of New Antiviral for Treatment …
StreetInsider.com
Chimerix (NASDAQ: CMRX) today announced results from preclinical studies supporting further evaluation of CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. CMX521 showed activity in vitro against all

and more »

Share this post:

Recent Posts